| Business Summary | | Vertex
Pharmaceuticals
Inc.
is
a
biotechnology
company
that
seeks
to
discover,
develop
and
commercialize
novel
small
molecule
drugs
that
address
significant
markets
with
major
unmet
medical
needs,
including
the
treatment
of
viral
diseases,
cancer,
auto-immune
and
inflammatory
diseases,
and
neurological
disorders.
The
Company's
drug
design
platform
integrates
advanced
biology,
chemistry,
biophysics
and
information
technologies
to
make
the
drug
discovery
process
more
efficient
and
productive.
To
date,
Vertex
has
discovered
and
advanced
one
product
that
has
reached
the
market,
including
the
HIV
protease
inhibitor
Agenerase
(amprenavir),
and
the
Company
has
12
additional
drug
candidates
in
development. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Vertex
Pharmaceuticals
discovers,
develops
and
markets
small
molecule
drugs
that
address
the
treatment
of
viral
diseases,
cancer,
autoimmune
and
inflammatory
diseases,
and
neurological
disorders.
For
the
six
months
ended
6/30/01,
total
revenues
rose
15%
to
$40.5
million.
Net
loss
before
accounting
change
rose
62%
to
$21
million.
Results
reflect
increased
amounts
earned
under
collaborative
R&D
agreements,
offset
by
higher
research
and
development
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Joshua Boger, Ph.D., 49 Chairman,
CEO | $678K | $5.5M | Vicki Sato, Ph.D., 52 Pres | 489K | 1.3M | John Alam, M.D., 39 Sr.
VP, Drug Evaluation and Approval | 283K | 2.1M | Mark Murcko, Ph.D. VP,
CTO and Chair of the Scientific Advisory Board | -- | -- | Lynne Brum, 37 VP,
Corp. Communications and Market Devel. | 206K | 2.4M | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|